Table 1.
Classification of ATMPs trials by disease area and phase of development
| Phase I and I/II | Phase II and II/III | Phase III | NA | Total | |
|---|---|---|---|---|---|
| Cancer | 146 (24.2%) | 69 (26.4%) | 18 (27.8%) | 233 (24.8%) | |
| Cardiovascular diseases | 104 (17.2%) | 67 (25.7%) | 11 (16.7%) | 182 (19.4%) | |
| Immune system/inflammation | 68 (11.3%) | 29 (11.1%) | 9 (13.9%) | 2 (22.2%) | 108 (11.5%) |
| Musculoskeletal system | 59 (9.8%) | 25 (9.6%) | 9 (13.9%) | 6 (66.7%) | 99 (10.5%) |
| Neurology | 61 (10.1%) | 23 (8.8%) | 1 (1.5%) | 85 (9.1%) | |
| GI diseases and diabetes | 25 (4.1%) | 15 (5.7%) | 8 (12.3%) | 1 (11.1%) | 49 (5.2%) |
| Ophthalmology | 34 (5.6%) | 7 (2.7%) | 3 (4.6%) | 44 (4.7%) | |
| Pulmonology | 25 (4.1%) | 6 (2.3%) | 1 (1.5%) | 32 (3.4%) | |
| Dermatology | 19 (3.1%) | 7 (2.7%) | 3 (4.6%) | 29 (3.1%) | |
| Haematology | 16 (2.6%) | 4 (1.5%) | 0 | 20 (2.1%) | |
| Others | 47 (7.8%) | 9 (3.4%) | 2 (3.1%) | 58 (6.2%) | |
| Total | 604 (64.3%) | 261 (27.9%) | 65 (6.9%) | 9 (0.9%) | 939 (100%) |
GI diseases: gastrointestinal diseases.
Notes: The table shows the number of ATMP trials in each disease area: cancer, cardiovascular diseases, immune system/inflammation, musculoskeletal system, neurology, GI diseases and diabetes, ophthalmology, pulmonology, dermatology, haematology, and others. In addition, it shows the percentage of ATMPs targeting every indication by phase of development.